Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

[1]  P. Ellis,et al.  A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. , 2010, Clinical lung cancer.

[2]  Qinghua Zhou,et al.  Comparisons between the National Comprehensive Cancer Network (NCCN) non‐small‐cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009 , 2010, Thoracic cancer.

[3]  E. Felip,et al.  Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Rossi,et al.  Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. , 2009, The oncologist.

[5]  A. Marrari,et al.  Multipeptide vaccination in cancer patients , 2009, Expert opinion on biological therapy.

[6]  S. Demaria,et al.  Systemic effects of local radiotherapy. , 2009, The Lancet. Oncology.

[7]  Cynthia S. Johnson,et al.  Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Czerniecki,et al.  Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer , 2008, Oncogene.

[9]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[10]  P. Ellis,et al.  Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Butts,et al.  Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers , 2005, Expert review of vaccines.

[12]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[13]  R. Livingston,et al.  Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Crowley,et al.  Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[16]  M. Smylie,et al.  Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. , 2001, Clinical lung cancer.

[17]  M. Fisher,et al.  Phase II and III trials: comparison of four chemotherapy regimens in advanced non small-cell lung cancer (ECOG 1594). , 2000, Clinical lung cancer.

[18]  M. Fisher,et al.  2000 Highlights From: 36th Annual ASCO Meeting; New Orleans, LA May 2000 , 2000 .

[19]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Miles,et al.  Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[21]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[23]  S. Zotter.  Tissue and tumor distribution of human polymorphic epithelial mucin , 1988 .